drug developer

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.

Regeneron Pharmaceuticals

Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.

New membership rules by PhRMA governing R&D spending come as the industry tries to change its image as profiteers of sickness and disease. 

A study from Yale researchers finds that about a third of new drugs, especially ones with accelerated approval, have safety issues, NPR reports.

Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

The company is recruiting patients with TRK fusions and different cancer types in a Phase II basket trial that may pave the way for a "molecular label" for its drug.

Pages

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.